CYP 2D6*4 polymorphism and interindividual response variation to metoprolol in stage 1 hypertensive patients: no association in a rural Indian population?

Background/aim: Genetic polymorphism of CYP2D6 shows diverse pharmacokinetic and pharmacodynamic variation. Therefore, the present work was designed to study the variation in therapeutic responses to metoprolol (MP) in stage 1 hypertensive patients and also aims to verify the association of CYP2D6*4 polymorphism and response variation in an Indian population for the first time.

Materials And Methods: Clinically, a total of 119 hypertensive patients and 116 healthy individuals as controls were included.